108 related articles for article (PubMed ID: 11457435)
41. Alpha-synuclein and transgenic mouse models.
Fernagut PO; Chesselet MF
Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
[TBL] [Abstract][Full Text] [Related]
42. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
[TBL] [Abstract][Full Text] [Related]
43. A pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of Aβ
Mahía A; Conde-Giménez M; Salillas S; Pallarés I; Galano-Frutos JJ; Lasa Í; Ventura S; Díaz-de-Villegas MD; Gálvez JA; Sancho J
Anal Bioanal Chem; 2019 Jan; 411(1):251-265. PubMed ID: 30411148
[TBL] [Abstract][Full Text] [Related]
44. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.
Galvin JE; Giasson B; Hurtig HI; Lee VM; Trojanowski JQ
Am J Pathol; 2000 Aug; 157(2):361-8. PubMed ID: 10934140
[TBL] [Abstract][Full Text] [Related]
45. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain.
Lowe R; Pountney DL; Jensen PH; Gai WP; Voelcker NH
Protein Sci; 2004 Dec; 13(12):3245-52. PubMed ID: 15537754
[TBL] [Abstract][Full Text] [Related]
46. Alpha-synuclein and neurodegenerative diseases.
Goedert M
Nat Rev Neurosci; 2001 Jul; 2(7):492-501. PubMed ID: 11433374
[No Abstract] [Full Text] [Related]
47. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein.
Arawaka S; Saito Y; Murayama S; Mori H
Neurology; 1998 Sep; 51(3):887-9. PubMed ID: 9748051
[TBL] [Abstract][Full Text] [Related]
48. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.
Giasson BI; Murray IV; Trojanowski JQ; Lee VM
J Biol Chem; 2001 Jan; 276(4):2380-6. PubMed ID: 11060312
[TBL] [Abstract][Full Text] [Related]
49. Alpha-synuclein aggregation and its relation to neurodegenerative diseases.
Papapetropoulos S; Mash DC
Ann Neurol; 2005 Apr; 57(4):605; author reply 605-6. PubMed ID: 15786478
[No Abstract] [Full Text] [Related]
50. alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy.
Sone M; Yoshida M; Hashizume Y; Hishikawa N; Sobue G
Acta Neuropathol; 2005 Jul; 110(1):19-26. PubMed ID: 15895299
[TBL] [Abstract][Full Text] [Related]
51. Binding of Thioflavin T and Related Probes to Polymorphic Models of Amyloid-β Fibrils.
Peccati F; Pantaleone S; Riffet V; Solans-Monfort X; Contreras-García J; Guallar V; Sodupe M
J Phys Chem B; 2017 Sep; 121(38):8926-8934. PubMed ID: 28851223
[TBL] [Abstract][Full Text] [Related]
52. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
[TBL] [Abstract][Full Text] [Related]
53. Nuclear localization of alpha-synuclein and its interaction with histones.
Goers J; Manning-Bog AB; McCormack AL; Millett IS; Doniach S; Di Monte DA; Uversky VN; Fink AL
Biochemistry; 2003 Jul; 42(28):8465-71. PubMed ID: 12859192
[TBL] [Abstract][Full Text] [Related]
54. Real-time analysis of amyloid fibril formation of alpha-synuclein using a fibrillation-state-specific fluorescent probe of JC-1.
Lee JH; Lee IH; Choe YJ; Kang S; Kim HY; Gai WP; Hahn JS; Paik SR
Biochem J; 2009 Mar; 418(2):311-23. PubMed ID: 19007333
[TBL] [Abstract][Full Text] [Related]
55. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
[TBL] [Abstract][Full Text] [Related]
56. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
Fujiwara H; Hasegawa M; Dohmae N; Kawashima A; Masliah E; Goldberg MS; Shen J; Takio K; Iwatsubo T
Nat Cell Biol; 2002 Feb; 4(2):160-4. PubMed ID: 11813001
[TBL] [Abstract][Full Text] [Related]
57. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.
Duda JE; Giasson BI; Mabon ME; Miller DC; Golbe LI; Lee VM; Trojanowski JQ
Acta Neuropathol; 2002 Jul; 104(1):7-11. PubMed ID: 12070658
[TBL] [Abstract][Full Text] [Related]
58. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.
Murray IV; Giasson BI; Quinn SM; Koppaka V; Axelsen PH; Ischiropoulos H; Trojanowski JQ; Lee VM
Biochemistry; 2003 Jul; 42(28):8530-40. PubMed ID: 12859200
[TBL] [Abstract][Full Text] [Related]
59. A Comparative Study of High-Contrast Fluorescence Lifetime Probes for Imaging Amyloid in Tissue.
Gorka F; Daly S; Pearson CM; Bulovaite E; Zhang YP; Handa A; Grant SGN; Snaddon TN; Needham LM; Lee SF
J Phys Chem B; 2021 Dec; 125(50):13710-13717. PubMed ID: 34883017
[TBL] [Abstract][Full Text] [Related]
60. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases.
Duda JE; Shah U; Arnold SE; Lee VM; Trojanowski JQ
Exp Neurol; 1999 Dec; 160(2):515-22. PubMed ID: 10619569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
